Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Sodium Iodide → Ziprasidone
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | Sodium Iodide | HCID 5238 | — |
| 반응물 | Sodium Carbonate | HCID 10340 | — |
| 반응물 | Ziprasidone Hydrochloride | HCID 219099 | — |
| 반응물 | 3-(1-Piperazinyl)-1,2-benzisothiazole | HCID 2772144 | — |
| 반응물 | 5-(2-Chloroethyl)-6-chlorooxindole | HCID 10609474 | — |
| 용매 | Methyl Isobutyl Ketone | HCID 7909 | — |
| 생성물 | Ziprasidone | HCID 60854 | — |
반응 단계
U.S. Pat. No. 4,831,031 discloses a process for the preparation of ziprasidone hydrochloride, which involves refluxing N-(1,2-benzisothiazol-3-yl)piperazine with 5-(2-chloroethyl)-6-chloro-oxindole in methyl isobutyl ketone in the presence of sodium iodide and sodium carbonate for about 40 hours followed by column chromatographic purification of the product to get ziprasidone base which is dissolved in methylene chloride and treated with ethereal hydrogen chloride to get ziprasidone hydrochloride salt. The salt is washed with acetone and the product is dried.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US08178674B2 |
| 출처 데이터셋 | uspto-grants-2012_05 |
| ORD ID | ord-a1fe5bcacab64580aac065d315eeeb4c |
| 출처 메모 | uspto-grants-2012_05 |